11 Stocks That Will Bounce Back According to Analysts

6. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)

Year-to-Date Performance: -34.72%

Average Price Target Upside Potential According to Analysts: 113.97%

Number of Hedge Fund Holders: 41

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is a clinical-stage pharmaceutical company that focuses on discovering, developing, and commercializing new therapies for endocrine diseases and endocrine-related tumors. CRNX ranks among stocks that will bounce back according to analysts.

The company is actively working to make its therapies accessible worldwide and support its global growth. Paltusotine, which is Crinetics Pharmaceuticals, Inc.’s (NASDAQ:CRNX) lead development candidate, is the first investigational once-daily, oral medicine that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. In March 2025, Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) reported that the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for paltusotine for the proposed treatment and long-term maintenance therapy of acromegaly. The application will now be reviewed by the Committee for Medicinal Products for Human Use (CHMP). Previously, the EMA had granted paltusotine Orphan Drug Designation (ODD) for the treatment of acromegaly in February 2025. In the US, the Food and Drug Administration (FDA) has also accepted the New Drug Application (NDA) by Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) for paltusotine, with a decision expected by September 25, 2025.